I ran FatsQC on a set of 4 Illumina PE exomes and got really weird graphs for the kmer distribution. I've never seen this pattern before - does anyone know what is going on and what to do about it?
-
-
I am not entirely sure about what is going on since I don't have the full length Illumina adapter sequences handy, but my guess is that the plot shows an adapter or primer dimer of some sort. Seeing that GGAAG is part of the start of the Illumina adapter (GATCGGAAGAGC..., wihtout the A-tail at the start) and the spacing is always the same this might simply be full-length adapter dimers. Such sequences should not align anywhere, so you probably don't need to worry about them. This doesn't mean that you don't have to trim your sample at all, this is difficult to say without seeing the rest of the plots. -
removing over-represented sequences does not help
@fkrueger: I found that two TruSeq adaptors were listed among the over-represented sequences in the fastqc report so I removed them for one of the samples and re-ran fastqc. The graph changed somewhat but there are still non-random peaks (below). Any ideas?
Comment
-
I don't know how you removed the adapters, but the k-mers could still result from adapter dimers. Trim Galore for example only removes the entire adapter sequence AGATCGGAAGAGC but only if it starts with the A from the A-tailing process. In your case the sequence seems to start with GATC(GGAAG) and thus wouldn't be affected by adapter trimming.
The CACAC and ACACA is often a highly occurring sequence in MeDIP-Seq or the like. I wouldn't worry too much about the plot for the moment, and only come back to it if you find that you've got an unusually low mapping efficiency or similar.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment